NCT06858709 Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
| NCT ID | NCT06858709 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongnan Hospital |
| Condition | Chemotherapy-induced Peripheral Neuropathy (CIPN) |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-03-20 |
| Primary Completion | 2027-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-03-20 with a primary completion date of 2027-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older, of any nationality. * Patients diagnosed with malignant tumor. * Eligible patients will report altered sensations and/or pain and/or other neurological symptoms, with a grade between 2-3 for chemotherapy-induced peripheral neuropathy on the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events-version 5.0 (NCI-CTCAE.v-5.0). * Predicted life expectancy of ≥3 months. * Intact skin without any breaches or purulent discharge. * Written informed consent by the patient before enrolment Patients must be able to comply with the study protocol, which includes attending the treatment sessions on time and completing the study questionnaires in accordance with the study protocol. Exclusion Criteria: * History of pre-existing peripheral neuropathy before chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, and toxic neuropathy. * Patients with skin damage, pus or scar at the acupuncture stimulation area. * Patients who are pregnant or breastfeeding. * Significant mental conditions. * Patients not fulfilling the inclusion criteria. * Patients receiving other acupuncture treatments during the trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06858709 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy-induced Peripheral Neuropathy (CIPN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06858709 currently recruiting?
Yes, NCT06858709 is actively recruiting participants. Contact the research team at haijunyu@whu.edu.cn for enrollment information.
Where is the NCT06858709 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06858709 clinical trial?
NCT06858709 is sponsored by Zhongnan Hospital. The trial plans to enroll 150 participants.